0000000000736053

AUTHOR

Michelle Sholzberg

showing 3 related works from this author

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials

2021

ABSTRACTEndothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterpri…

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Hospitalized patientsbusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)law.inventionClinical trialRandomized controlled triallawAntithromboticmedicineIllness severityIntensive care medicinebusiness
researchProduct

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

2021

Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and ar…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industrymedicine.drug_classAnticoagulantState of the art review030204 cardiovascular system & hematologymedicine.diseaseThrombosislaw.inventionClinical trial03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawAntithromboticMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessIntensive care medicineJournal of the American College of Cardiology
researchProduct